Drug intelligence / Profile preview

LM716

Development stage: Unknown
Lead developer: Novartis

Overview

LM716 is an investigational drug developed by Novartis for the treatment of neoplasms, specifically unspecified solid tumors in oncology. The precise mechanism of action for LM716 remains unknown, and it does not represent a novel mechanistic class. The drug has been evaluated in at least one Phase 1 clinical trial for oncology solid tumors but has not received regulatory approval or any special FDA designation. No adverse events have been reported in the available data, and there are no approved indications or countries where it is marketed[1].

Beyond the preview

Go deeper on LM716.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LM716.

Explore the full profile